Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 82.35

-4.5%

Jan 8 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1780)	5/3/2007 12:29:16 PM
From: Jibacoa	Read Replies (1) of 3722

BSM has been up to 9% today, after reporting that patients with inoperable Stage IV head and neck cancer with metastatic lymph nodes, that were treated with hyperthermia added to radiation showed complete response (tumor disappearance) from 41% to 83%, local relapse- free survival from 24% to 68% & overall survival at 5Yrs. from 0% to 53%, as compared to radiation treatments alone. The study, was published in the International Journal of Radiation Oncology & was halted at 41 patients because, due to the strongly favorable results from the addition of hyperthermia therapy to radiation, it was not considered ethical to enroll further patients in the study who would be denied the combined treatment. biz.yahoo.com bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next